~~<i id='09D576E839'><strike id='09D576E839'><tt id='09D576E839'><pre id='09D576E839'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：explore 2025-08-04 03:39:54 - browse：4652

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Elizabeth Holmes banned from government health programs

knowledge

leisure time

entertainment

knowledge

hotspot

Injusttwoweeks,thebrutalityoftheIsrael-Hamasconflicthasshockedtheworld.Butoneofitsmostheartbreakinga

WSS

Senate panel to vote on hospitals, PBMs, prisoner care

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

New brain studies show LSD's effects on the brain in full color

FDA clears AI tool for detecting skin cancer

Readout Newsletter: What happened with Sarepta's Duchenne data

WHO may add ‘noma' to its list of neglected tropical diseases

leisure time

entertainment

knowledge

In Memoriam: Notable people who died in 2023

Cassava reveals details — and problems — with Alzheimer's study

How to save PrEP access — and even expand it

FDA has safety concerns on CRISPR

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

State Dept. review finds Biden bears some blame for Afghanistan failures

Biden's order seeks to regulate AI risk without stifling innovation

Heart attack and stroke risk calculators need revising

FDA clears AI tool for detecting skin cancer

leisure time

Paying for Covid pills will soon shift to insurers

Why doctors need education on FDA device approval process

Medtronic CEO on promising devices for diabetes, hypertension

Think you might have Covid

FDA clears AI tool for detecting skin cancer

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

entertainment

entertainment

knowledge

hotspot